Despite being pulled down by currency headwinds and the US HPV overhang, Qiagen’s Q2 15 results managed to beat not only market expectations (albeit marginally) but also the company’s own guidance for the quarter – revenue grew 5% CER (2% contribution from acquisitions), ahead of the 4% CER guidance and better than the 2% and 4% CER growth reported in Q1 15 and Q2 14, respectively. Currency and US HPV issues, while significant, were also lower than guided – currency im
11 Aug 2015
Strong results; growth drivers on track
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong results; growth drivers on track
Despite being pulled down by currency headwinds and the US HPV overhang, Qiagen’s Q2 15 results managed to beat not only market expectations (albeit marginally) but also the company’s own guidance for the quarter – revenue grew 5% CER (2% contribution from acquisitions), ahead of the 4% CER guidance and better than the 2% and 4% CER growth reported in Q1 15 and Q2 14, respectively. Currency and US HPV issues, while significant, were also lower than guided – currency im